What is PEPG's current stock price?

PEPG (PepGen Inc.) is currently trading at $1.51 with a market cap of $104.4M.

What sector is PepGen Inc. in?

PepGen Inc. (PEPG) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PEPG a good stock to buy?

Analysts have a Buy consensus on PEPG with a price target of $5.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PEPG PepGen Inc.

Healthcare

$1.51-1.95%ClosedMarket Cap: $104.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.78

P/S

0.00

EV/EBITDA

-0.98

DCF Value

$1.01

FCF Yield

-74.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-59.9%

ROA

-49.4%

ROIC

-54.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-17.8M	$—
Q4 null	$0.00	$-18.3M	$—
FY null	$0.00	$-89.7M	$—
Q3 null	$0.00	$-18.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$5.50

Target (Median)

$5.50

Target Range

$4.00 - $7.00

0 Strong Buy6 Buy0 Hold0 Sell1 Strong Sell

WedbushOutperform

2026-05-13

WedbushOutperform

2026-04-01

GuggenheimBuy

2026-02-18

HC Wainwright & Co.Buy

2025-11-13

WedbushOutperform

2025-09-30

Trading Activity

Insider Trades

View All

STRECK PAULofficer: EVP, Head of R&D

SellFri Mar 06

STRECK PAULofficer: EVP, Head of R&D

SellFri Mar 06

McArthur James Gdirector, officer: President and CEO

SellFri Mar 06

McArthur James Gdirector, officer: President and CEO

SellFri Mar 06

Donnelly Noelofficer: Chief Financial Officer

SellFri Mar 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.01

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Peers